Startseite>>Signaling Pathways>> Others>>FPH1 (BRD-6125)

FPH1 (BRD-6125) (Synonyms: FPH1)

Katalog-Nr.GC14922

FPH1 (BRD-6125)(BRD-6125) erhÖht die Anzahl und AktivitÄt primÄrer menschlicher Hepatozyten in vitro und fÖrdert die Differenzierung von iPS-Zellen hin zu einer hepatischen Linie.

Products are for research use only. Not for human use. We do not sell to patients.

FPH1 (BRD-6125) Chemische Struktur

Cas No.: 708219-39-0

Größe Preis Lagerbestand Menge
10mg
65,00 $
Auf Lager
25mg
137,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

FPH1 is a small molecule that promotes the functional proliferation of primary hepatocytes [1].

FPH1 belongs to the functional proliferation hits which are screened out by their ability to permit renewable sourcing of functional human hepatocytes. This ability of FPH1 is not dependent on the donors of the hepatocytes. It has been found that FPH1 was active against the primary human hepatocytes from six cell sources of genetically diverse individuals. Besides that, FPH1 can affect the hepatocyte functions with promoting albumin secretion during the differentiation of iPS cells into iHeps. Moreover, treatment of FPH1 also resulted in the increase of CYP3A4 levels and the decrease of AFP secretion [1].

References:
[1] Shan J, Schwartz R E, Ross N T, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nature chemical biology, 2013.

Bewertungen

Review for FPH1 (BRD-6125)

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FPH1 (BRD-6125)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.